Project Grant R21CA309636
Award Date 7/16/26
Completion Date 6/30/28
Dollars Obligated $404K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85287, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $671,226 Project Grant to the University of California, San Diego on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an innovative microbial therapeutic platform for colorectal cancer prevention and treatment. The award supports a five-year research initiative (through April 30, 2031) focused on engineering native Escherichia coli bacteria derived from host microbiota to durably colonize the...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded The Ohio State University a $386,888 Project Grant on July 2, 2026, with a completion date of June 30, 2028. This award supports research to characterize the Lachnospiraceae bacterial family and establish the mechanistic pathways by which these gut microbiota enhance response to immune checkpoint blockade (ICB) cancer immunotherapy. The project applies comparative...
- Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Grant Award Summary Yale University received a $432,125 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2028. The award funds research to engineer Salmonella enterica serovar Typhimurium-based immunotherapeutic platforms targeting immunologically "cold" solid tumors that exhibit limited responsiveness to conventional immunotherapy. The research will develop three integrated technological...
- Federal Grant Award Summary Arizona State University received a $3.13 million Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on August 22, 2025, with a completion date of July 31, 2029. This research initiative, titled "The Ecology of Barrett's Esophagus," aims to develop advanced computational and machine learning methods to improve the prediction and diagnosis of esophageal adenocarcinoma (EA) progression in...
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park Comprehensive Cancer Center in Buffalo, NY received a $446,112 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2026 through August 31, 2028. The award supports research to develop enhanced targeted therapies for colorectal cancer (CRC), the second leading cause of cancer-related deaths. The research will investigate the synergistic effects of...